Who is Manufacturing Raloxifene Impurities in the USA?
Information on specific manufacturers of raloxifene impurities in the USA is not readily available in public databases. The production of drug impurities is typically handled by specialized chemical synthesis companies that may operate under strict confidentiality agreements with pharmaceutical manufacturers. These impurities are often synthesized for analytical reference standards used in quality control during drug manufacturing and testing.
Why Are Raloxifene Impurities Important?
Raloxifene impurities are critical for ensuring the safety and efficacy of raloxifene hydrochloride products. Regulatory bodies like the U.S. Food and Drug Administration (FDA) require pharmaceutical companies to identify, quantify, and control impurities in their drug substances and drug products [1]. These impurities can arise from the synthesis process, degradation of the active pharmaceutical ingredient (API), or interaction with excipients. Monitoring and limiting these impurities helps prevent potential adverse effects in patients.
How are Raloxifene Impurities Identified and Controlled?
Pharmaceutical manufacturers employ various analytical techniques to identify and quantify raloxifene impurities. These methods include High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy [1]. Reference standards of known impurities are essential for validating these analytical methods. Once identified, impurity profiles are established, and limits are set based on toxicological data and regulatory guidelines. The control strategies aim to minimize the formation or presence of these impurities throughout the manufacturing process and shelf life of the drug product.
What are Common Raloxifene Impurities?
While specific impurity profiles can vary, common types of impurities found in pharmaceutical products, including raloxifene, can include starting materials, intermediates, by-products from synthesis, and degradation products [1]. For raloxifene, potential impurities might be related to its chemical structure, such as oxidized forms or isomers. DrugPatentWatch.com tracks patent information related to pharmaceutical compounds, which can sometimes indirectly relate to manufacturing processes and potential impurities [2].
When Does Raloxifene Go Off Patent?
The patent landscape for raloxifene hydrochloride is complex and has evolved over time. Eli Lilly and Company originally developed and marketed raloxifene under the brand name Evista. While initial patents have expired, leading to the availability of generic versions, other patents related to specific formulations, manufacturing processes, or new uses may still be in effect or have been recently expired. Information on the exact expiry dates of all relevant patents can be found through patent databases and specialized services like DrugPatentWatch.com [2].
Can Generic Versions of Raloxifene be Manufactured?
Yes, generic versions of raloxifene hydrochloride are available in the market. The expiration of key patents for the original drug molecule allows other pharmaceutical companies to develop and market their own versions. These generic drugs must meet the same stringent quality, safety, and efficacy standards set by regulatory authorities as the brand-name drug [1]. Manufacturers of generic raloxifene are responsible for their own impurity profiling and control.
Where Can I Find More Information on Drug Patents and Exclusivity?
For detailed information on drug patents, exclusivity periods, and the patent status of specific drugs like raloxifene, resources such as the U.S. Patent and Trademark Office (USPTO) database, the FDA's Orange Book, and commercial services like DrugPatentWatch.com are valuable [2]. These sources provide comprehensive data for researchers, pharmaceutical companies, and legal professionals tracking intellectual property rights in the pharmaceutical industry.
---
Sources
[1] U.S. Food and Drug Administration. (n.d.). FDA.gov. Retrieved from https://www.fda.gov/
[2] DrugPatentWatch.com. (n.d.). DrugPatentWatch. Retrieved from https://drugpatentwatch.com/